RegulatoryUpdated April 202613 min read

Peptide Sciences Shut Down: What Happened and Where to Go Now

64K people per month are searching for answers. Here’s what the Peptide Sciences shutdown means for you and where to find legitimate access to peptides in 2026.

What happened to Peptide Sciences?

If you've tried to visit PeptideSciences.com recently, you already know the answer: the site is gone. The largest and most well-known grey-market peptide vendor in the United States shut down in early 2026 following a wave of FDA enforcement actions that have fundamentally reshaped access to research peptides in this country.

For tens of thousands of people—an estimated 64,000 per month are still searching for “Peptide Sciences”—this shutdown was not just an inconvenience. It was the end of the primary supply chain they relied on for compounds like BPC-157, TB-500, CJC-1295/Ipamorelin, and dozens of other peptides used for recovery, cognition, metabolic optimization, and growth hormone support.

Here is the timeline of what happened, why it happened, and what comes next.

The timeline

The net effect: the grey-market infrastructure that supplied peptides to hundreds of thousands of Americans is gone. Some of it was shut down by the FDA. Some of it collapsed on its own. And the regulatory landscape is simultaneously tightening enforcement on unregulated sellers while expanding legal access through licensed compounding pharmacies.

Why did peptide vendors shut down?

The grey-market peptide industry operated for years in a legal grey zone that was never truly grey—it was simply unenforced. Understanding why the FDA moved when it did requires looking at three converging factors: regulatory reclassification, safety concerns, and political pressure.

The “research chemical” fiction collapsed

Companies like Peptide Sciences, Amino Asylum, and dozens of smaller vendors sold peptides labeled “for research purposes only” or “not for human consumption.” This labeling was a legal fig leaf. Everyone involved—vendors, customers, and regulators—understood that the overwhelming majority of these peptides were being purchased for self-injection by individuals managing their own health protocols.

The vendors provided reconstitution instructions. Customer forums discussed dosing protocols openly. Payment was processed through standard merchant accounts. The entire ecosystem was built around personal use, with the “research” label serving as a liability shield that the FDA ultimately decided to pierce.

In enforcement actions throughout 2025, the FDA made clear that it views intent and actual use as more relevant than labeling. When a company sells a reconstitution kit alongside a peptide vial to an individual consumer, the “research only” defense does not hold.

Category 2 restrictions tightened the legal window

The FDA's 2024 bulk drug substance rule placed 19 peptides into Category 2, a designation that prevents them from being compounded by licensed 503A and 503B pharmacies while the FDA evaluates their safety and efficacy profiles. The Category 2 list included some of the most widely used compounds in the optimization community:

With licensed pharmacies unable to compound these substances, the grey market became the only source. This created a perverse dynamic: the FDA's own restrictions pushed more consumers toward unregulated vendors, which in turn gave the FDA stronger justification for enforcement. The agency argued—with some merit—that the grey market was a public health risk precisely because these compounds lacked the quality controls that licensed pharmacies provide.

Quality and safety concerns were real

This is the part that is uncomfortable for the peptide community to acknowledge, but it matters: the grey market had genuine quality problems. Independent testing conducted by third parties throughout 2024 and 2025 found that approximately 40% of grey-market peptides tested had incorrect dosages—either significantly overdosed or underdosed relative to what was on the label.

Some samples contained bacterial endotoxins. Others contained compounds that did not match the label at all. A small but non-trivial percentage were contaminated with heavy metals or other manufacturing byproducts.

This is not to say that all grey-market peptides were dangerous. Many users ran their own third-party tests and sourced from vendors with relatively consistent quality. Peptide Sciences, in particular, had a better reputation than most for providing Certificates of Analysis. But “better than most” in an unregulated market is a low bar. Without mandatory cGMP (current Good Manufacturing Practice) compliance, batch-to-batch consistency was never guaranteed.

40% of tested grey-market peptides had incorrect dosages. This is not a fringe quality issue—it is a systemic failure of an unregulated supply chain.

The political calculus shifted

The FDA's enforcement posture did not change in a vacuum. Two dynamics drove the timing. First, the GLP-1 agonist market (semaglutide, tirzepatide) generated massive pharmaceutical industry revenue, and grey-market compounders and vendors were cutting into that revenue by offering cheaper alternatives. Pharmaceutical lobbying for enforcement was well-documented throughout 2024 and 2025.

Second, the incoming administration under President Trump appointed Robert F. Kennedy Jr. as HHS Secretary, and RFK's public statements favored expanding access to peptides through legitimate channels rather than allowing unregulated markets to continue. The enforcement actions against grey-market vendors can be understood partly as clearing the field before reopening legal access through compounding pharmacies.

Check your protocol status

If you were sourcing peptides from Peptide Sciences, Amino Asylum, or another grey-market vendor, the first question you need to answer is whether your specific compound is currently available through legal channels—and if not, when it is expected to become available again. Use the tool below to check the current regulatory status of your protocol.

Protocol Status Checker

Find out if your compound is legally available and what your options are.

The RFK reclassification: what it means

On February 27, 2026, HHS Secretary Robert F. Kennedy Jr. made the single most significant announcement for peptide access since the Category 2 restrictions went into effect. Speaking publicly, Kennedy stated that approximately 14 of the 19 peptides placed in Category 2 would be moved back to Category 1, restoring their eligibility for legal compounding by licensed 503A and 503B pharmacies.

This announcement was significant for several reasons, and its implications are still unfolding.

What the reclassification means practically

Category 1 status means that a peptide can be legally compounded by a licensed pharmacy when prescribed by a physician for an individual patient. This is the standard pathway for compounded medications in the United States. It requires:

For the estimated hundreds of thousands of Americans who were using Category 2 peptides, this reclassification means a return to legal, quality-controlled access. You will need a physician to prescribe the compound, and you will need to source it from a licensed pharmacy—but both of those requirements existed before the grey market emerged, and the infrastructure to support them is already in place.

Which peptides are expected to return to Category 1

Kennedy's announcement referenced approximately 14 of 19 compounds. While the specific list has not been published in the Federal Register at the time of this writing, public statements and reporting suggest the following peptides are expected to move to Category 1:

The remaining five compounds are expected to remain in Category 2 or potentially move to Category 3 (ineligible for compounding), likely due to insufficient safety data or overlap with existing FDA-approved products.

What has not happened yet

It is important to understand what the Kennedy announcement is and is not. As of April 2026:

The expectation within the regulatory and compounding pharmacy community is that the formal rule will be published in Q2 2026, with compounding eligibility restored shortly thereafter. Several large 503B outsourcing facilities have publicly stated they are prepared to resume production within weeks of the formal publication.

Where to get legitimate peptides in 2026

The grey-market shutdown does not mean peptides are unavailable. It means the access pathway has changed. For many compounds—including GLP-1 agonists like semaglutide and tirzepatide, as well as several growth hormone secretagogues and healing peptides—legitimate, physician-supervised access is available right now. For Category 2 compounds pending reclassification, legal access is expected to resume within months.

Here are your current options, ranked by quality of care and regulatory compliance.

Physician-supervised telehealth clinics

Telehealth clinics that specialize in hormone optimization and peptide therapy offer the most accessible path to legitimate peptide access. These clinics provide physician consultations, lab work interpretation, and ongoing protocol management—and they source compounds exclusively from licensed compounding pharmacies.

The leading clinics in this space include:

These clinics are not identical. They differ in pricing, physician accessibility, protocol aggressiveness, and the range of compounds they prescribe. But they share one critical characteristic: they source exclusively from licensed pharmacies, and every prescription is written and monitored by a licensed physician.

Compounding pharmacies (503A and 503B)

If you already have a relationship with a prescribing physician—an endocrinologist, a functional medicine doctor, or an anti-aging specialist—you can have peptide prescriptions filled directly at a licensed compounding pharmacy.

There are two types of compounding pharmacies relevant to peptide access:

503B facilities generally offer lower per-unit costs because they produce in larger batches, and they provide more rigorous testing documentation. If your physician is willing to prescribe peptides, a 503B pharmacy is typically the best combination of quality assurance and affordability.

Important: you need a prescription

All legitimate peptide access in 2026 requires a physician's prescription. This is not a new requirement—it has always been the legal standard for injectable peptides intended for human use. The grey market circumvented this requirement by labeling products as “research chemicals,” but that pathway is closed.

If you do not currently have a prescribing physician, the telehealth clinics listed above are the fastest path to establishing one. Most can schedule an initial consultation within one to two weeks, and many can coordinate lab work in advance so that your first appointment is actionable rather than purely diagnostic.

What about Nuletic?

We are building Nuletic as the platform we wished existed when we started our own optimization protocols. Physician-supervised peptide and hormone therapy, AI-powered protocol management, pharmaceutical-grade sourcing from licensed 503B pharmacies, and transparent lab tracking. We are not yet live, but you can join the waitlist to get notified when we launch.

What to avoid

The shutdown of Peptide Sciences and other major vendors has not eliminated the grey market entirely. New vendors have emerged, some operating from overseas, others attempting to replicate the “research chemical” model domestically. These vendors are not safe alternatives. Here is what to avoid and why.

Grey-market vendors still operating

Several vendors continue to sell peptides online using the same “research use only” labeling that Peptide Sciences used. These vendors are operating in direct violation of FDA guidance, and their continued operation is likely temporary. The FDA has demonstrated that it is actively pursuing enforcement, and purchasing from these vendors carries both legal and health risks.

Do not interpret a vendor's continued operation as evidence that it is legitimate. The FDA enforcement process takes time—warning letters, investigations, and seizure actions do not happen overnight. A vendor that is currently online may already be under investigation.

Overseas sources

Chinese and other overseas peptide manufacturers have always been part of the supply chain—many grey-market vendors sourced their raw materials internationally and performed finishing and lyophilization domestically. With domestic vendors shutting down, some consumers are attempting to order directly from overseas manufacturers.

This is the highest-risk option available. Overseas manufacturers selling directly to consumers are not subject to any US regulatory oversight. Quality testing, if it exists at all, is conducted by the manufacturer itself with no independent verification. Customs seizure is common. And the compounds you receive may bear no meaningful relationship to what is described on the label.

“Research use only” products

Any vendor selling injectable peptides to individual consumers with a “research use only” label is selling an unapproved drug. Full stop. The FDA has made its position on this unambiguous. The label does not create a legal safe harbor for the vendor, and it does not protect you as the consumer.

The contamination risk is real

The 40% incorrect-dosage statistic bears repeating because it is the single most important data point in this entire discussion. When you purchase a peptide from an unregulated vendor, you have approximately a four-in-ten chance that what you are injecting does not match what you think you are injecting.

This is not a theoretical risk. Incorrect dosing in peptides can have real consequences. Overdosed growth hormone secretagogues can cause water retention, carpal tunnel symptoms, and blood sugar dysregulation. Underdosed compounds are therapeutically useless, meaning you are injecting a substance with no benefit while still assuming the risks of injection (infection, immune response, injection site reactions).

Contaminated compounds introduce risks that are even more serious: bacterial endotoxins can cause fever, inflammatory responses, and in severe cases sepsis. Heavy metal contamination from improper manufacturing can accumulate over time with chronic use.

If you are injecting a compound into your body, you deserve pharmaceutical-grade quality assurance. That is not an opinion—it is a minimum standard of care that the grey market was structurally unable to provide.

Social media “sources”

In the wake of the vendor shutdowns, peptide sourcing discussions have migrated to private Telegram groups, Reddit communities, and social media direct messages. Individuals and small operations are offering to sell or broker peptides through these channels. These sources have even less accountability than the established grey-market vendors did. There is no quality testing, no recourse if the product is contaminated or fake, and no way to verify what you are receiving.

Do not source peptides through social media, messaging apps, or anonymous online communities. The risks are not worth the cost savings.

The bottom line

The grey-market era of peptide access in the United States is over. Peptide Sciences, Amino Asylum, and the ecosystem of unregulated vendors that served hundreds of thousands of Americans have been shut down by FDA enforcement, and they are not coming back.

This is not entirely bad news. The grey market existed because legitimate access was unnecessarily restricted. The RFK reclassification announcement signals that the federal government recognizes this, and the return of approximately 14 peptides to Category 1 compounding status will restore legal access through channels that are genuinely safer than what the grey market provided.

In the interim, legitimate options exist. GLP-1 agonists like semaglutide and tirzepatide are legally compoundable now. Several growth hormone secretagogues and healing peptides are expected to follow in Q2 2026. And physician-supervised telehealth clinics can provide access, monitoring, and protocol management that the grey market never offered.

If you were a Peptide Sciences customer, the path forward is clear:

At Nuletic, we are building the platform that makes this entire process seamless: physician-supervised protocols, pharmaceutical-grade sourcing, AI-powered optimization, and full transparency from lab work to compound sourcing. We believe your biology deserves the same rigor you would apply to managing your wealth.

Join our waitlist to get early access when we launch.

ShareX / Twitter|LinkedIn|

Get notified when Nuletic launches

Physician-supervised peptide and hormone therapy. Join the waitlist.

No spam. Unsubscribe anytime.

Related guides

Peptide Therapy: The Complete GuideGuideAre Peptides Legal? 2026 GuideLegalBest Online TRT Clinics in 2026Comparison

Medical disclaimer: This content is for informational purposes only and does not constitute medical advice. Always consult a licensed physician before starting any peptide or hormone therapy. Written by Val Narodetsky. Medical review pending.

Join Waitlist